This article was highlighted for PRO+ subscribers, Seeking Alpha's service for professional investors. Find out how you can get the best content on Seeking Alpha here.
With the dust settling from the JP Morgan Healthcare conference in mid-January, a name that is rising above the noise is Strongbridge Biopharma (SBBP), a stock that is not yet pricing in an opportunity to solve a major unmet medical need and create significant shareholder value. While this rare disease-focused company is successfully marketing its first commercial product, Keveyis, a treatment for primary periodic paralysis, or PPP associated